GLP-1 Obesity Drug Pioneers Propose Radical Shift: Ditch GLP-1 Target for New Hormone Combo

The foundational scientists behind blockbuster obesity drugs like Zepbound are now challenging the core premise of their own success. A research team led by Richard DiMarchi and Matthias Tschöp is advancing a provocative hypothesis: targeting the GLP-1 hormone may be unnecessary for potent weight loss. Their new experimental drug, detailed in a peer-reviewed draft paper, activates receptors for the GIP and glucagon hormones instead, suggesting a potential paradigm shift in the multi-billion dollar metabolic drug landscape.

This research, funded by biotech BlueWater Biosciences, is based on studies in rodents and monkeys. The data indicates that this GIP/glucagon-targeting molecule, when administered at high doses, could achieve weight loss comparable to current GLP-1-inclusive drugs like Eli Lilly's Zepbound. Crucially, the early animal studies suggest this approach might sidestep the significant tolerability issues—notably nausea and vomiting—that are common side effects of the approved GLP-1-based treatments.

The proposal, if validated, could disrupt the strategic focus of major pharmaceutical players heavily invested in the GLP-1 pathway. However, the hypothesis remains just that—a hypothesis based on preclinical data. The critical caveat, acknowledged by the researchers, is that results in animals frequently fail to translate in human clinical trials. The next essential step is confirmation in human studies, a high-risk, high-reward phase that will determine if this is a scientific curiosity or the foundation for a next-generation obesity therapy.